Trial Profile
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAXAR
- Sponsors TRACON Pharmaceuticals
- 01 Jul 2021 Results published in the Oncologist
- 15 Oct 2020 Status changed from completed to discontinued.
- 30 Jul 2020 This trial has been discontinued in United Kingdom according to European Clinical Trials Database record.